Skip to main content

Advertisement

SpringerLink
Log in

Clinical and Experimental Evaluation of Diagnostic Significance of Alpha-Fetoprotein and Osteopontin at the Early Stage of Hepatocellular Cancer

  • Published:
Bulletin of Experimental Biology and Medicine Aims and scope

We evaluated the possibility of using an experimental model of hepatocellular carcinoma to study oncomarkers of primary liver cancer and compared the diagnostic efficacy of alpha-fetoprotein and osteopontin in the experiment and in clinical practice. Experimental studies were performed on a model of hepatocellular carcinoma induced by administration of diethyl nitrosamine to Fisher-344 rats. In addition, the levels of α-fetoprotein and osteopontin were determined in 35 patients with hepatocellular carcinoma detected at stages I-II according to TNM classification. The proposed model of liver cancer in rats reflects the sequence of stages characteristic of hepatocellular carcinoma in humans: liver fibrosis—cirrhosis—cancer. This model is applicable for the study of tumor markers at the early stage of tumor development. Osteopontin was found to have a more powerful diagnostic potential then alpha-fetoprotein.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Breder VV, Kosyrev VY, Kudashkin NE, Laktion KK. Hepatocellular carcinoma as a social and medical problem in the Russian Federation. Med. Sovet. 2016;(10):10-18. Russian.

    Article  Google Scholar 

  2. Ivashkin VT, Mayev IV, Kaprin AD, Agapov MYu, Andreev DN, Vodoleev AS, Zharkova MYu, Korolev MP, Kucheryavyi YuA, Lapina TL, Mayevskaya MV, Okhlobystin AV, Pavlov ChS, Paraskevova AV, Pirogov SS, Poluektova EA, Rumyantseva DE, Trukhmanov AS, Tsarkov PV, Sheptulin AA, Shifrin OS. Early detection of oncological diseases of the digestive system (Guidelines of the Russian Gastroenterological Association and the Russian Association of Oncologists for Primary Care Physicians). Ross. Zh. Gastroenterol., Gepatol., Koloproktol. 2019;29(5):53-74. Russian.

  3. Malov SI, Malov IV, Dvornichenko VV, Rasulov RI, Kuvshinov AG, Marche PN, Decaens T, Macek-Jilkova Z, Yushchuk ND. Application of alpha-fetoprotein and osteopontin combination for early diagnosis of hepatocellular carcinoma associated with hepatitis C. Klin. Lab. Diagnost. 2019; 64(10):607-612. Russian.

    Article  CAS  Google Scholar 

  4. Al-Zoubi S, Wassouf A, Zetoune AB. Measuring levels of osteopontin as potential biomarker for hepatocellular carcinoma in Syrian patients. Gastroenterol. Hepatol. Bed Bench. 2017;10(2):97-101.

    PubMed  PubMed Central  Google Scholar 

  5. Aubé C, Oberti F, Lonjon J, Pageaux G, Seror O, N’Kontchou G, Rode A, Radenne S, Cassinotto C, Vergniol J, Bricault I, Leroy V, Ronot M, Castera L, Michalak S, Esvan M, Vilgrain V; CHIC Group. EASL and AASLD recommendations for the diagnosis of HCC to the test of daily practice. Liver Int. 2017;37(10):1515-1525.

    Article  Google Scholar 

  6. Bai DS, Zhang C, Chen P, Jin SJ, Jiang GQ. The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. Sci. Rep. 2017;7(1):12870. https://doi.org/10.1038/s41598-017-12834-1

  7. Castello LM, Raineri D, Salmi L, Clemente N, Vaschetto R, Quaglia M, Garzaro M, Gentilli S, Navalesi P, Cantaluppi V, Dianzani U, Aspesi A, Chiocchetti A. Osteopontin at the crossroads of inflammation and tumor progression. Mediators Inflamm. 2017;2017:4049098. https://doi.org/10.1155/2017/4049098

  8. Duarte-Salles T, Misra S, Stepien M, Plymoth A, Muller D, Overvad K, Olsen A, Tjønneland A, Baglietto L, Severi G, Boutron-Ruault MC, Turzanski-Fortner R, Kaaks R, Boeing H, Aleksandrova K, Trichopoulou A, Lagiou P, Bamia C, Pala V, Palli D, Mattiello A, Tumino R, Naccarati A, Bueno-de-Mesquita HB, Peeters PH, Weiderpass E, Quirós JR, Agudo A, Sánchez-Cantalejo E, Ardanaz E, Gavrila D, Dorronsoro M, Werner M, Hemmingsson O, Ohlsson B, Sjöberg K, Wareham NJ, Khaw KT, Bradbury KE, Gunter MJ, Cross AJ, Riboli E, Jenab M, Hainaut P, Beretta L. Circulating osteopontin and prediction of hepatocellular carcinoma development in a large European population. Cancer Prev. Res. (Phila). 2016;9(9):758-765.

    Article  CAS  Google Scholar 

  9. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol. 2018;69(1):182-236.

  10. Jilkova ZM, Kuyucu AZ, Kurma K, Ahmad Pour ST, Roth GS, Abbadessa G, Yu Y, Schwartz B, Sturm N, Marche PN, Hainaut P, Decaens T. Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma. Oncotarget. 2018;9(13):11,145-11,158.

    Article  Google Scholar 

  11. Sengupta S, Parikh ND. Biomarker development for hepatocellular carcinoma early detection: current and future perspectives. Hepat. Oncol. 2017;4(4):111-122.

    Article  Google Scholar 

  12. Singal AG, Mittal S, Yerokun OA, Ahn C, Marrero JA, Yopp AC, Parikh ND, Scaglione SJ. Hepatocellular carcinoma screening associated with early tumor detection and improved survival among patients with cirrhosis in the US. Am. J. Med. 2017;130(9):1099-1106.e1.

    Article  Google Scholar 

  13. Tanaka J, Akita T, Ko K, Miura Y, Satake M; Epidemiological Research Group on Viral Hepatitis and its Long-term Course, Ministry of Health, Labour and Welfare of Japan. Countermeasures against viral hepatitis B and C in Japan: an epidemiological point of view. Hepatol. Res. 2019;49(9):990-1002.

    Article  Google Scholar 

  14. Torres-Mena JE, Salazar-Villegas KN, Sánchez-Rodríguez R, López-Gabiño B, Del Pozo-Yauner L, Arellanes-Robledo J, Villa-Treviño S, Gutiérrez-Nava MA, Pérez-Carreón JI. Aldo-Keto reductases as early biomarkers of hepatocellular carcinoma: a comparison between animal models and human HCC. Dig. Dis Sci. 2018;63(4):934-944.

  15. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat. Rev. Gastroenterol. Hepatol. 2019;16(10):589-604.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinique Universitaire d’Hépato-gastroentérologie, Pôle Digidune, CHU Grenoble Alpes, La Tronche, France

    Z. Macek-Jilkova & T. Decaens

  2. Institute for Advanced Biosciences, Research Center, University Grenoble-Alpes, Grenoble/Inserm U 1209/CNRS 5309, La Tronche, France

    Z. Macek-Jilkova, K. Kurma, C. Charrat, T. Decaens & P. N. Marche

  3. Irkutsk State Medical University, Ministry of Health of the Russian Federation, Irkutsk, Russia

    S. I. Malov, N. P. Peretolchina & I. V. Malov

  4. A. I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of the Russian Federation, Moscow, Russia

    N. D. Yushchuk

Authors
  1. Z. Macek-Jilkova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. I. Malov
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Kurma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Charrat
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T. Decaens
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N. P. Peretolchina
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P. N. Marche
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. I. V. Malov
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. N. D. Yushchuk
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. I. Malov.

Additional information

Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 170, No. 9, pp. 334-339, September, 2020

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Macek-Jilkova, Z., Malov, S.I., Kurma, K. et al. Clinical and Experimental Evaluation of Diagnostic Significance of Alpha-Fetoprotein and Osteopontin at the Early Stage of Hepatocellular Cancer. Bull Exp Biol Med 170, 340–344 (2021). https://doi.org/10.1007/s10517-021-05063-0

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10517-021-05063-0

Key Words

Search

Navigation